Mn Services Vermogensbeheer B.V. Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Mn Services Vermogensbeheer B.V. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 41,213 shares of the biopharmaceutical company’s stock after buying an additional 713 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Regeneron Pharmaceuticals were worth $31,811,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Private Advisory Group LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $216,000. ORG Partners LLC boosted its stake in Regeneron Pharmaceuticals by 81.6% in the 4th quarter. ORG Partners LLC now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 31 shares in the last quarter. Northwest Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $366,000. Woodstock Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 12.3% during the fourth quarter. Woodstock Corp now owns 18,646 shares of the biopharmaceutical company’s stock worth $14,392,000 after purchasing an additional 2,036 shares during the period. Finally, Chesley Taft & Associates LLC lifted its position in Regeneron Pharmaceuticals by 184.4% during the fourth quarter. Chesley Taft & Associates LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 802 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the topic of a number of recent analyst reports. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Canaccord Genuity Group raised their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Stock Up 1.6%

Regeneron Pharmaceuticals stock opened at $749.29 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The stock’s fifty day simple moving average is $765.00 and its 200-day simple moving average is $709.34. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $79.21 billion, a P/E ratio of 18.03, a P/E/G ratio of 1.98 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the business posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Activity

In other news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.